Browse Interferon topic

Subtopics (18)

• Control
• Dosage and administration
• Drug use
• Genetic aspects
• Government finance
• Growth
• Health aspects
• Innovations
• Intellectual property
• Laws, regulations and rules
• Market research
• Market size
• Physiological aspects
• Product development
• Product enhancement
• Reports
• Research
• Usage

Articles

Title	Author	Type	Date	Words
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009.			Nov 3, 2009	871
Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C.			Oct 31, 2009	1356
ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb.			Oct 27, 2009	699
Strand of RNA may help predict survival prospects for patients with liver cancer.			Oct 26, 2009	904
India : Amarillo partners Intas in interferon-alpha lozenge trials to treat influenza in India.			Oct 12, 2009	222
Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009.			Oct 1, 2009	897
Medtronic Initiates Phase II Hepatitis C Clinical Study "COPE-HCV" to Determine Tolerability and Safety of Continuous Interferon Infusion for Patients with HCV.		Clinical report	Sep 2, 2009	726
FDA APPROVES AVASTIN FOR THE MOST COMMON KIDNEY CANCER.			Sep 1, 2009	798
(SCI) TURKISH RESEARCHERS SUCCEED IN PRODUCING THERAPEUTIC PROTEIN FROM TRANSGENIC RATS.			Aug 26, 2009	248
Switzerland : Novartis says FDA approves interferon drug for MS.			Aug 17, 2009	176
FDA Approves Avastin for the Most Common Type of Kidney Cancer.			Aug 3, 2009	1512
New interferon response could offer early control of bird flu virus.			Jun 20, 2009	286
Disruption of Immune-System Pathway Key Step in Cancer Progression, Stanford Study Shows.			May 18, 2009	797
Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C.			Apr 24, 2009	1125
Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C.			Apr 24, 2009	1095
Reportlinker Adds World Growth Factors (Blood and Tissue) Market Report.			Mar 24, 2009	3865
Neovacs Announces the Publication of a PNAS Article on Anti-IFN Kinoid Active Immunization in Lupus.			Mar 16, 2009	340
Stem cells may stop osteoporosis, promote bone growth.			Mar 5, 2009	351
ZymoGenetics Collaboration with Bristol-Myers Squibb Clears Review Under Hart-Scott-Rodino Antitrust Improvements Act.			Mar 2, 2009	401
Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound.			Jan 12, 2009	1226
Key Challenges and Issues facing the World Growth Factors (Blood And Tissue) Market.			Jan 8, 2009	3786
Novel leads from Heliotropium ovalifolium, 4, 7, 8-trimethoxy-naphthalene-2-carboxylic acid and 6-hydroxy-5, 7-dimethoxy-naphthalene-2-carbaldehyde show specific IL-6 inhibitory activity in THP-1 cells and primary human monocytes.	Kulkarni-Almeida, Asha; Suthar, Ashish; Goswami, Hitesh; Vishwakarma, Ram; Chauhan, Vijay Singh; Bal	Report	Dec 1, 2008	4260
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections.	Kaul, Rupert	Report	Dec 1, 2008	413
BioSante Pharmaceuticals Announces Receipt of NIH Grant for Inhaled Interferon.			Nov 17, 2008	827
Early Trigger for Type-1 Diabetes Found in Mice, Stanford Scientists Report.			Aug 26, 2008	761
Security services will face any vandalism act in Sidi Ifni with 'necessary firmness', minister.			Aug 21, 2008	363
Genetic differences may predict response to interferon treatment.		Brief article	Jun 22, 2008	56
BaroFold Inc. Initiates First Human Studies for Multiple Sclerosis Drug Candidate, BaroFeron(TM).			Jun 16, 2008	555
VioQuest Pharmaceuticals Presents Phase 1 Data Showing Promising Immune Response and Safety Profile of Lenocta(TM).			Jun 2, 2008	1289
Alnylam and Collaborators Publish Research on the Immunostimulatory Properties and Mechanisms of Certain siRNAs in Mammalian Cells.			Apr 28, 2008	1028
Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment.		Financial report	Apr 24, 2008	2030
Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments.			Apr 23, 2008	1706
COPAXONE(R) Significantly Reduced Annual Relapse Rates and Stabilized Disease Progression in Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment.		Clinical report	Apr 10, 2008	1566
Perlegen and SC Liver Research Consortium to Collaborate on Interferon Response in Hepatitis C Patients.			Feb 19, 2008	472
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma.			Feb 1, 2008	1135
Valeant Pharmaceuticals Sells Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC for $91 Million.			Dec 20, 2007	856
Amarillo Biosciences Files Patent Application to Treat Chronic Cough with Oral Interferon.			Dec 4, 2007	436
Learning from HIV: how will drug resistance influence treatment strategies against hepatitis C?	Durantel, David; Zoulim, Fabien		Dec 1, 2007	2922
Phage Biotechnology Corp. Engages The Bruckner Group to Find a Joint Commercialization Partner for Phage's Portfolio of Recombinant Protein Biopharmaceuticals, Technologies, and Development Platforms.			Nov 15, 2007	897
Phage Biotechnology Corp. Engages The Bruckner Group To Find A Joint Commercialization Partner For Phage's Portfolio Of Recombinant Protein Biopharmaceuticals, Technologies, and Development Platforms.			Nov 6, 2007	1004
Flamel Technologies Announces Positive Top Line Results of a Clinical Trial of IFN-alpha-XL versus PegIntron(TM) in Patients with Chronic Hepatitis C Virus Infection.			Oct 25, 2007	1057
Amarillo Biosciences Issues Clinical Trials Update.			Oct 9, 2007	1042
Super-sentinel chickens and detection of low-pathogenicity influenza virus.	Marcus, Philip I.; Girshick, Theodore; van der Heide, Louis; Sekellick, Margaret J.		Oct 1, 2007	2191
Drug combination cures hepatitis C.	Wagner, Elizabeth	Brief article	Sep 1, 2007	154
Mechanisms of action of etanercept in psoriasis.	Wood, E.J.	Drug overview	Sep 1, 2007	319
Dutton Associates Announces Investment Opinion: Amarillo Biosciences Rating Maintained At Speculative Buy By Dutton Associates.			Jun 6, 2007	414
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer.		Clinical report	Jun 2, 2007	1233
HEMISPHERX/ARMADA TO LAUNCH ALFERON N INJECTION.			Jun 1, 2007	645
Data Suggest that PEGASYS(R) May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron(R).		Clinical report	May 21, 2007	1571
Hemispherx and Armada Health Care enter Agreement to Launch Alferon N Injection(R) via Specialty Pharmacy Network.			Apr 23, 2007	830
Investors Financial Network, Pioneers of Successful Real Estate Investing Strategy, Now Lists Properties Nationwide.			Apr 19, 2007	351
Dutton Associates Announces Investment Opinion: Amarillo Biosciences Rating Maintained at Speculative Buy by Dutton Associates.			Apr 16, 2007	440
Polymorphism and Depression in HCV patients.	MacNeil, Jane Salodof	Brief article	Jan 1, 2007	245
Schering obtains United States patent.		Brief article	Nov 1, 2006	70
Customizing Treatment with PEGASYS(R) May Improve Chances for Success in Hepatitis C.		Clinical report	Oct 27, 2006	2103
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment.		Clinical report	Oct 3, 2006	1038
Music Industry Gets Covered by Launch of The indieFINANCIALnetwork(TM).			Sep 15, 2006	608
Hemispherx Biopharma Announces Purchase of Royalty Interest from Stem Cell Innovations, Inc.; Only Natural Alpha Interferon Product on the U.S. Market.			Aug 1, 2006	657
Hemispherx Biopharma to Present at The First International Conference on Avian Influenza in Humans at the Pasteur Institute; Novel Therapeutic Approach Attacks Virus at 3 Levels Simultaneously.			Jun 27, 2006	823
Hemispherx Biopharma to Present at the Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference; Company's Biodefense Shield and Avian Influenza Program Highlighted.			Jun 15, 2006	830
Eminent Scientist Receives $100,000 Lemelson-MIT Lifetime Achievement Award; Dr. Sidney Pestka Recognized for Groundbreaking Research on Anti-Viral Treatments.			May 3, 2006	1213
3 New Studies Show Hemispherx Biopharma's Ampligen(R) and Alferon(R) LDO May Provide Defense against Avian Flu.			Feb 16, 2006	1304
Novel Interferon Signaling Pathways Explored in Special Issue of Journal of Interferon & Cytokine Research.			Dec 28, 2005	584
Hemispherx to Present at the 4th Annual Biodefense Research Meeting Sponsored by the American Society of Microbiology; Ampligen(R) and Alferon(R) in Global Clinical / Animal Trials Against Avian Influenza.			Dec 20, 2005	619
Hemispherx Highlighted in Study of Innate Immunity as a Defense Against Bio-terror Threats; Ampligen(R) and Alferon(R) Featured in the December 2005 Journal of Allergy and Clinical Immunology.			Dec 13, 2005	928
Hemispherx Biopharma to Present at the New York Society of Security Analysts 9th Annual Healthcare Industry Conference; New Influenza Treatment / Prevention Initiatives Introduced.			Dec 12, 2005	525
DEEPNINES OFFERS NETWORK PROTECTION IN SINGLE APPLIANCE.			Dec 1, 2005	489
Hemispherx Biopharma Enters Research Agreement with Defence R&D Canada.			Nov 29, 2005	950
Advanced Biotherapy Issues Stockholders Newsletter.			Nov 29, 2005	830
Synairgen: interferon-Beta Enters Clinic For Novel Use.			Nov 15, 2005	485
The hepatitis C drug development pipeline.	Raymond, Daniel		Sep 22, 2004	2442
My personal experience in being HCV/HIV co-infected & how I cured hepatitis C.	Levin, Jules		Sep 22, 2004	1482
Viragen granted United States patent for manufacture of Multiferon.			Jul 1, 2004	470
The effects of a herbal medicine (Mao-to) in patients with chronic hepatitis C after injection of IFN-[beta].	Kainuma, M.; Sakai, S.; Sekiya, N.; Mantani, N.; Ogata, N.; Shimada, Y.; Terasawa, K.		Jan 1, 2004	3904
Roche CMV-prevention drug Valcyte approved for wider distribution by European Union.		Brief Article	May 30, 2003	244
ISIS obtains United States patent.		Brief Article	May 1, 2003	70
Sustained virologic response possible in HCV. (Role of the Psychiatrist is Critical).	Brunk, Doug	Brief Article	Feb 1, 2003	687
Hepatitis C and interferon treatments.		Brief Article	Sep 22, 2002	205
How the immune system eliminates mosquito-borne viruses--new insights. (EH Update).		Brief Article	May 1, 2002	406
Early HCV treatment may prevent chronic disease.			Dec 1, 2001	1095
Biopharma Heads Into Second Phase of Hepatitis C Study.	Webb, Marion	Brief Article	Apr 23, 2001	467
Interferon delays multiple sclerosis.	N.S.	Brief Article	Oct 28, 2000	409
Schering-Plough exercises option to develop and commercialize one of Human Genome Sciences' discoveries.		Brief Article	Oct 1, 2000	301
Genentech applies for patent.		Brief Article	Mar 1, 2000	40
Cleveland Clinic obtains United States patent.			Aug 1, 1999	49
BIOGEN ANTICIPATES RECORD SALES/NET INCOME FOR 1998.			Feb 1, 1999	544
Ribavirin Capsules and Interferon alfa-2b.			Nov 1, 1998	1389
Maxim Pharmaceuticals Announces Collaboration With BioNative AB; Phase II Trial of Maxamine Therapy for the Treatment of Renal Cell Carcinoma Planned for Fall 1998.		Article	Sep 14, 1998	772
Schering-Plough in agreements resolving alpha interferon patent dispute		Article	Jun 1, 1998	552
Amarillo Biosciences receives "buy" recommendation from Biovest Research.			Jun 30, 1997	188
Amarillo Biosciences announces a new clinical trial in hepatitis C patients.			May 12, 1997	347
Amarillo Biosciences Inc. appoints Thomas W. D'Alonzo to Board of Directors.			Mar 20, 1997	227
Viragen appoints Mount Sinai CEO Fred Hirt to its board of directors.		Biography	Jan 13, 1997	327
Roferon-A now licensed for treatment of chronic hepatitis C.			Nov 11, 1996	689
Interferon Sciences announces senior staff appointments.			Sep 30, 1996	541
Lawsuit filed in Federal Court alleges willful infringement of Berlex patent by Biogen.			Jul 3, 1996	538
Viragen Inc. Obtains Commitment for $50 Million Financing; Company Closes $15 Million First Stage.			Jun 10, 1996	228
Enrollment of HIV-Infected Patients Initiated in Nationwide Low Dose Oral Alpha Interferon Study.			Jun 6, 1996	605
Viragen Inc. Common Stock to commence trading on NASDAQ SmallCap Market.			Jun 3, 1996	136
Interferon Sciences receives U.S. patent for Type I interferon receptor protein.			May 30, 1996	334